Testosterone vs Testosterone Cypionate — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Androgen

Testosterone

Brand: AndroGel

First FDA approval: 2002-10-31

Androgen

Testosterone Cypionate

Brand: AZMIRO

First FDA approval: 1979-07-25

Lowest NADACAcquisition cost floor across all NDCs

$0.442Per unit

$1.88Per unit

Average NADACAcross all dosage forms and strengths

$26.66Up to $316.92

$7.89Up to $14.14

Generic manufacturersActive ANDA holders — FDA Orange Book

1428 total ANDAs filed

1016 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$145.9MFull year

$61.3MFull year

Part D claims (CY24)Total fills, all strengths

864K251K beneficiaries

1.7M529K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$169Per claim, all NDCs

$36Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1687Substantial friction

816Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes14 manufacturers

Yes10 manufacturers